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Background. The unique distribution of the alleles for
the Duffy antigen receptor complex (DARC) that binds to
chemokines may be associated with the rates of acute re-
jection and delayed allograft function (DGF) among African
Americans.
Methods. A prospective, multicenter cohort study enrolled
222 African American recipients of cadaveric renal allografts
from eight adult transplant centers. Subjects were typed by
allele-specific polymerase chain reaction (ASPCR) for the poly-
morphism at position 535 that determines the level of transcrip-
tion. Associations of DARC genotypes were examined in Cox
hazards models with episodes of acute rejection and in logistic
regression models with the development of DGF.
Results. FyB Null homozygosity was observed among 67% of
the recipients. Fifteen percent of the study cohort experienced
at least one episode of acute rejection, and the incidence of
DGF was 42.5%. The number of FyB Null alleles and FyB Null
homozygosity had no detectable association with the rate of
acute rejection (P > 0.50) or with the development of DGF
(P > 0.50).
Conclusion. The susceptibility of African American recipi-
ents to acute rejection and to DGF was not confirmed to be as-
sociated with DARC alleles or genotype. Future studies should
exclude a potential role of donor-related DARC in transplant
outcomes.
Transplantation of renal allografts significantly im-
proves the survival of individuals with end-stage renal
disease (ESRD). However, the duration of allograft sur-
vival is not uniform across recipient ethnic groups. In the
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United States, the five-year allograft survival of white
recipients is 66.2% compared with a more abbreviated
duration of functioning allografts for black recipients of
54.4% [1]. Several nonimmunologic reasons have been
proposed to explain the foreshortened allograft survival
of black recipients [2]. Studies that have explored allelic
variants of genes that might determine the differential
rate of allograft function associated with recipient ethnic-
ity have been limited to antigens associated with the hu-
man leukocyte antigen (HLA) system [3] and chemokine
receptors such as CCR2 and CCR5 [4, 5].
Chemokines are cellular attractants that have de-
fined roles in directing movements of neutrophils and
cells necessary for the initiation of the T-cell response.
Chemokines attract monocytes, effector T cells, and im-
mature dendritic cells to sites of inflammation [6], facil-
itating the interaction of T cells and antigen-presenting
cells, promoting allorecognition that can lead to rejection
[6, 7]. Further, chemokines attract neutrophils to sites
of ischemia and contribute to alloantigen-independent
injury to transplanted organs [8]. The potential roles
of chemokines in allograft function are illustrated by
antibody blockade or targeted deletion of particular
chemokines in rodents, resulting in reduced inflamma-
tory, vascular, and interstitial changes in allografts [6–8].
The normal functioning of chemokines requires bind-
ing to their respective receptors. However, binding of
CC chemokines [regulated on activation normal T-cell
expressed and secreted (RANTES), monocyte chemoat-
tractant protein-1 (MCP-1)] and CXC chemokines
[interleukin-8, melanoma growth-stimulatory factor
(MGSA)] to the Duffy antigen receptor complex
(DARC) does not result in signal transduction [9, 10]. The
absence of DARC expression in mouse knock-out models
leads to more intense inflammatory infiltrates in organs
after exposure to lipopolysaccharide [11, 12]. These and
other findings support the hypothesis that DARC binds to
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chemokines, limiting systemic inflammation by reducing
circulating levels of chemokines.
The DARC antigens are a clinically significant blood
group system expressed on erythrocyte membranes, ca-
pable of producing hemolytic disease of the newborn
and hemolytic transfusion reactions. The DARC antigens,
Fy(a) and Fy(b), are codominantly expressed, and the al-
leles, FyA and FyB, are encoded on chromosome 1. FyA
and FyB differ by a single base substitution at nucleotide
position 1205, which results in the substitution of aspartic
acid for glycine at residue position 44 [13]. The Fy(a- b-)
phenotype is the result of a silent FyB allele that arises
through the substitution of thymine to cytosine at nu-
cleotide 535. This single nucleotide polymorphism (SNP)
disrupts transcription of the gene [14]. There is extensive
linkage disequilibrium between the SNPs at nucleotide
positions 535 and 1205, such that the FyB allele resulting
from thymine substitution at nucleotide 1205 is always
present with the SNP at nucleotide 535 that produces the
FyB Null allele as determined by restriction fragment
length polymorphisms [13]. The distribution of DARC
antigens varies in different ethnic groups because the null
phenotype, Fy (a- b-), is more common in African popula-
tions than Caucasians [15]. Duffy serves as a receptor for
Plasmodium vivax, and its absence is associated with in-
creased resistance to infection and may confer a survival
advantage where malaria is endemic.
We hypothesize that absence of DARC expression con-
tributes, in part, to the heightened immune response to
renal allografts and foreshortened allograft survival ob-
served among African American recipients. In addition,
the absence of DARC expression might increase the re-
sponse of the innate immune system that does not require
recognition of foreign antigens to damage allografts, re-
sulting in delayed allograft function (DGF). The objec-
tive of this investigation was to examine the potential
association of allelic variants that alter the expression of
DARC on erythrocytes with the susceptibility of African
American recipients to DGF and acute rejection.
METHODS
Patients
A prospective cohort study enrolled recipients of ca-
daveric renal allografts transplanted during 1997 to 2002
from eight transplant centers in eastern Pennsylvania
within the Gift of Life Donor Program (Hospital of the
University of Pennsylvania, Thomas Jefferson University
Hospital, Hahneman University Hospital, Albert Ein-
stein Medical Center, Lankenau Hospital, Hershey Med-
ical Center, Geisinger Medical Center, and Lehigh Valley
Hospital). The unique distribution of DARC alleles as-
sociated with ethnicity creates population stratification,
which may produce spurious associations of DARC and
renal allograft function [16, 17]. As a strategy to minimize
ethnic admixture (i.e., confounding by ethnicity), as well
as to increase the proportion of subjects with the FyB Null
allele to improve the precision of the estimates of asso-
ciations, this present investigation was limited to African
American recipients. Patients were consented for partic-
ipation at the time of transplantation or at a subsequent
outpatient visit at the local transplant clinic. This proto-
col was approved by the Institutional Review Boards at
each of the participating centers.
Data
Whole blood that remained from routine clinical test-
ing was used as the source of recipient DNA. Data re-
lated to donor and recipient characteristics at the time
of transplantation (e.g., ethnicity, gender, age) were col-
lected in a prospective manner from patient interviews.
Post-transplantation characteristics were prospectively
abstracted from inpatient and outpatient medical records
at six-month intervals. The first primary outcome for this
analysis was a presumed episode of acute rejection within
the first year post-transplant, defined by the initial use
of antibody therapy (OKT3, thymoglobulin, antithymo-
cyte globulin, or antilymphocyte globulin) or two or more
doses of intravenous methylprednisolone after the first
72 hours post-transplant. The second primary outcome,
delayed allograft function (DGF), was the requirement
for dialytic therapy of any duration within the first week
post-transplant.
Genotyping
DNA was extracted from whole blood specimens or
from buffy coats using Qiagen blood DNA extraction kits
(Valencia, CA, USA). Alleles of DARC were determined
by allele-specific polymerase chain reaction (ASPCR)
Four separate genotyping reactions were performed on
each genomic DNA sample using the primers described
by Hessner et al [18]. Two microliters (lL) of sample
DNA (50 ng/lL) were added to a mixture of 2 lL of
10× (AmpliTaq; Roche Applied Science, Indianapolis,
IN, USA), 0.2 lL of Tag gold (5 U/lL), 0.4 lL of forward
and reverse primers (20 lmol/L), 0.2 lL of 20 micromolar
(lmol/L) forward and reverse human growth hormone
primers, 0.4 lL of 10 mmol/L dNTPs, in 10 mmol/L Tris-
HCL, pH 8.3, 50 mmol/L KCl, 1.5 mmol/L MgCl2, in a
total reaction volume of 20 lL. Samples were amplified
on a Peltier type thermal cycler using the following pro-
gram: for FyA primers−94◦C for 10 minutes, 35 cycles at
94◦C for 30 seconds, 58◦C for 30 seconds, and 72◦C for
1 minute; for FyB primers−94◦C for 10 minutes, 35 cycles
at 94◦C for 30 seconds, 56◦C for 30 seconds, and 72◦C for
2 minutes. All amplified samples were subjected to a final
extension step at 72◦C for 10 minutes, and then stored at
4◦C until electrophoresis.
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Table 1. Distribution of FyB Null genotypes
Eligible subjects Final cohort
(N = 222) (N = 181)
FyB Null/FyB Null 66.7% 69.7%
FyB Null/non-FyB Null 28.4% 26.0%
Non-FyB Null/non-FyB Null 4.9% 4.3%
Hardy-Weinberg Equilibrium P = 0.28 P = 0.20
Statistical analysis
Descriptive analysis. The analyses of this investigation
focused on the SNP at position 535 because the function-
ality of the DARC gene related to chemokine binding is
associated with the allele at this locus and the high level
of linkage disequilibrium [17] between this locus and the
locus at nucleotide 1235. The distributions of the alleles
and genotypes among the entire cohort were examined
for the presence of Hardy-Weinberg equilibrium (HWE)
[19]. Recipients were divided into two groups based on
the genotype: individuals who were homozygous for the
FyB Null allele, and individuals with other genotypes.
Continuous variables were compared by nonparametric
testing. Frequencies of categorical variables were com-
pared by chi-square testing.
Quantitative analysis. Cox proportional hazards mod-
els were fit to examine the independent association of the
number of FyB Null alleles, or the FyB Null genotype of
DARC with the time to the first episode of acute rejec-
tion within the first year post-transplant. Multivariable
models were fit with the factors that had unadjusted as-
sociations (P < 0.10) with DARC genotypes. Logistic re-
gression analysis was utilized to examine the associations
of the FyB Null genotype and the number of FyB Null al-
leles with the odds of the development of DGF. The same
algorithmic strategy as implemented for acute rejection
was used to develop a multivariable model. All analy-
ses were performed using SAS 8.01 (Cary, NC, USA).
P values were two-sided.
RESULTS
DARC alleles and genotype frequencies
A total of 222 African Americans received a cadaveric
renal allograft during the study. The frequencies of alleles
and genotypes observed in the study population did not
differ significantly from what was expected under Hardy-
Weinberg equilibrium (P value = 0.28) (Table 1).
The examination of the association of the DARC gene
with the time to acute rejection, as well as the devel-
opment of DGF, entailed the exclusion of six recipients
because of primary nonfunction (allograft nephrectomy)
of the allograft, and of 35 recipients who had no available
follow-up data. Among this final group of 181 subjects, the
most common genotype was homozygosity for the FyB
Null allele (69.6%), and FyB Null allele was the most fre-
Table 2. Baseline characteristics
FyB Null Other FyB
homozygous Null genotype P value
Donor
Mean age 39.70 42.50 0.29
Male % 63.64 57.75 0.40
Black % 18.88 19.72 0.88
Recipient
Mean age 49.00 50.60 0.39
Male % 66.22 56.76 0.17
Cause of end-stage renal disease %
Diabetes 26.92 36.84 0.17
Hypertension 79.23 78.95 0.97
Glomerulonephritis 12.31 12.28 0.99
Interstitial nephritis 1.50 3.50 0.39
HLA mismatches 0.69
0 2.70 5.56
1–2 6.76 11.11
3–4 56.76 33.33
5–6 33.78 50.00
Mean cold ischemia time hours 19.2 18.9 0.74
Most recent PRA % 0.09
0 85.27 75.00
0–20 6.98 11.76
>20 7.75 13.24
Previous transplant
Yes % 12.40 12.28 0.98
Delayed graft function
Yes % 41.54 49.12 0.34
Induction therapy
Yes % 25.38 28.07 0.70
Initial calcineurin inhibitor % 0.86
Tacrolimus 38.46 40.35
Cyclosporine 58.46 57.89
Other 3.08 1.75
quent (76.7%), consistent with previous studies that have
reported a predominance of the FyB Null allele among
non-Caucasians [11]. The data for the remaining 181 sub-
jects remained consistent with HWE for this locus (P =
0.20).
DARC and baseline characteristics
The baseline characteristics of the cohort according to
the FyB Null genotype of the recipient are presented in
Table 2. The causes of end-stage renal disease (ESRD)
are not mutually exclusive, and hypertension is most fre-
quent in the cohort as anticipated from the ethnicity of
the recipients. There are no factors that have a statisti-
cally significant association with the genotypes. There is
an indication of a possible association between FyB Null
genotype and levels of panel reactive antibodies (PRA)
(P = 0.09).
DARC genotype and episodes of acute rejection
At least one episode of acute rejection occurred
among 16.0% of the cohort during the first year post-
transplant. The Kaplan-Meier curves in Figures 1A and B
present the rejection-free survival according to the num-
ber of FyB Null alleles and to the FyB Null genotype,
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Fig. 1. The rate of acute rejection within the first year post-transplant
according to the number of FyB Null alleles (A). The rate of acute
rejection within the first year post-transplant according to the FyB Null
homozygosity or other genotype (B).
respectively. There were no detectable unadjusted asso-
ciations of acute rejection with the number of alleles or
these genotypes (P = 0.66 and P = 0.83 by log rank tests,
respectively) (Fig. 1A and B). As well, there were no de-
tectable unadjusted associations in Cox models between
the number of FyB Null alleles (P = 0.83) or with the FyB
Null genotype (P = 0.59) and the rate of acute rejection
(Table 3). The absence of detectable associations between
FyB Null genotype or the number of FyB Null alleles
with acute rejection persisted after adjustment for most
recent PRA (Table 4). Adjusting for the levels of HLA
mismatching, type of calcineurin inhibitor at the time of
transplantation, and the use of antibody induction ther-
apy, previously described factors that have associations
with acute rejection, by forcing these variables into the
model did not impact the observations.
DARC genotype and delayed allograft function
The incidence of DGF was 42.5%. In an unadjusted
model, as well as after adjustment for most recent PRA,
Table 3. Unadjusted association of DARC gene and acute rejection
Hazard ratio 95% CIa P value
Number of FyB Null 0.83
alleles (vs. two)
Zero 1.54 0.36–6.62
One 1.12 0.49–2.56
FyB Null homozygosity 0.76 0.40–1.44 0.40
(vs. other FyB
Null genotype)
aCI denotes confidence interval.
Table 4. Adjusted association of DARC gene and acute rejection
Adjusted
hazard ratioa 95% CIb P value
Number of FyB Null 0.76
alleles (vs. two)
Zero 1.70 0.39–7.42
One 1.15 0.49–2.70
FyB Null homozygosity 0.81 0.37–1.78 0.60
(vs. other FyB
Null genotype)
aAdjusted for levels of most recent panel of reactive antibodies.
bCI denotes confidence interval.
Table 5. Unadjusted association of DARC gene and DGF
Odds ratio 95% CIa P value
Number of FyB Null 0.09
alleles (vs. two)
Zero 0.21 0.03–1.76
One 1.67 0.85–3.28
FyB Null homozygosity 0.76 0.40–1.44 0.40
(vs. other FyB
Null genotype)
aCI denotes confidence interval.
there was no apparent trend in the association between
the odds of DGF and FyB Null genotype or the number
of FyB Null alleles (Tables 5 and 6). Consideration of the
duration of cold ischemia time in the adjusted model did
not impact the observations.
DISCUSSION
The present study examined the relationship between
allelic variants of the DARC gene and acute rejection
and DGF among African American recipients or cadav-
eric renal allografts. Homozygosity for the FyB Null al-
lele was the most prevalent genotype and the FyB Null
allele was most frequent, consistent with previous inves-
tigations. However, an association of the allelic variants
of DARC within this group of recipients with the rate of
acute rejection and the odds of DGF was not detected.
DARC binds to various types of chemokines and
prevents the binding of chemokines to receptors, im-
pairing an inflammatory response. Selective pressure by
nature has created the prevalence of an allele that pre-
vents the expression of DARC on erythrocytes among
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Table 6. Adjusted association of DARC gene and DGF
Adjusted
odds ratioa 95% CIb P value
Number of FyB Null 0.12
alleles (vs. two)
Zero 0.23 0.03–1.99
One 1.70 0.83–3.47
FyB Null homozygosity 0.74 0.38–1.46 0.39
(vs. other FyB
Null genotype)
aAdjusted for levels of most recent panel of reactive antibodies.
bCI denotes confidence interval.
African Americans that might lead to heightened activ-
ity of inflammatory cells and plausibly increase the risk
for events post-transplant that are detrimental to allo-
graft survival. Immunocytochemistry studies confirm that
DARC expression is not limited to erythrocytes and oc-
curs in the endothelium of glomeruli, peritubular capil-
laries, vasa recta, and principal cells of collecting ducts
in normal kidney tissue [20, 21]. Several recent investiga-
tions revealed that the expression of DARC is unlikely
to be constitutive within the kidney because the expres-
sion is up-regulated in renal allografts during episodes
of acute rejection [22, 23]. The present investigation uti-
lized a DNA-based method to genotype for an allelic vari-
ant that has well-described functional implications on the
transcription of the DARC gene. However, the alteration
of the expression of the DARC genes associated with
the allelic variant considered in this study is erythroid-
specific; persons who are serologically negative for Duffy
expression on erythrocytes can still express the protein in
other tissues [20].
A recent investigation enrolled 163 African Ameri-
can recipients of renal allografts from Emory University
who were serologically typed for DARC. The majority
(71.8%) of the study population was Duffy negative Fy (a-
b-), and this phenotype did not have an association with
allograft survival that attained statistical significance (P =
0.169). Further, no descriptive association was observed
between episodes of acute rejection within six months
post-transplant and the serologic Duffy type [24]. How-
ever, the conclusions from this investigation may have
been limited by the accuracy of serologic methods to de-
termine the absence of Duffy expression due to variation
in strength of antibody reactions both within and between
various anti-FyB reagents [25, 26], and the proportion
of immature erythrocytes that continue to manufacture
protein in peripheral blood between subjects [27]. The
DNA-based method used here obviated these concerns
and allowed for the opportunity of a more conclusive in-
vestigation. This study, in agreement with the previous
serologic study, did not reveal an association between
DARC genotype and AR and DGF. There are several
possible interpretations for our findings. First, the level
of erythrocyte expression of DARC may be unimportant
in the immune response to an allograft. Second, a rela-
tionship could not be excluded between the genotypic
expression of donor-related DARC and transplant out-
comes. Third, the DARC gene in isolation does not de-
termine the susceptibility to acute rejection or to DGF.
There are several limitations to this study. First, we
cannot exclude with certainty that the DARC gene may
have an association with acute rejection that is dependent
upon products of other genes that have immune-related
functions, such as interleukins 4 and 10, which were not
considered in this study. Second, potential misclassifica-
tion of acute rejection (phenotypic heterogeneity) would
have led to an underestimation of effects because this
observational study did not require all episodes of acute
deterioration of renal function to be defined by a biopsy.
Third, the severity of DGF represented by the duration
of the need for dialysis post-transplant was not consid-
ered in this investigation, and we cannot eliminate the
possibility that DARC impacts duration of DGF. Fourth,
although genotyping error may result in misclassification
of individuals and obscure true associations, this was not
suggested by the presence of HWE. Finally, the magni-
tude of associations of the allelic variants of DARC may
have not have been detectable with the sample size of this
investigation.
CONCLUSION
The susceptibility of African American recipients to
acute rejection or to DGF according to recipient-related
variants of the DARC gene was not observed. Investiga-
tion of variants of this gene that are related to the ex-
pression of DARC within renal tissue (i.e., donor-related
variants), should be considered in future investigations.
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